Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy Of Baricitinib in Patients With Moderate-To-Severe Rheumatoid Arthritis Up to 6.5 Years Of Treatment: Results Of A Long-Term Study.
Caporali R, Taylor PC, Aletaha D, Sanmartí R, Takeuchi T, Mo D, Haladyj E, Bello N, Zaremba-Pechmann L, Fang Y, Dougados M. Caporali R, et al. Among authors: zaremba pechmann l. Rheumatology (Oxford). 2024 Jan 22:keae012. doi: 10.1093/rheumatology/keae012. Online ahead of print. Rheumatology (Oxford). 2024. PMID: 38258434
Comparative Effectiveness, Time to Discontinuation, and Patient-Reported Outcomes with Baricitinib in Rheumatoid Arthritis: 2-Year Data from the Multinational, Prospective Observational RA-BE-REAL Study in European Patients.
Alten R, Burmester GR, Matucci-Cerinic M, Salmon JH, Östör A, Ng KJ, Gerwien J, Zaremba-Pechmann L, Brnabic AJM, Fautrel B. Alten R, et al. Among authors: zaremba pechmann l. Rheumatol Ther. 2023 Dec;10(6):1575-1595. doi: 10.1007/s40744-023-00597-3. Epub 2023 Sep 27. Rheumatol Ther. 2023. PMID: 37755648 Free PMC article.
Efficacy and Safety of Empagliflozin According to Background Diuretic Use in HFrEF: Post-Hoc Analysis of EMPEROR-Reduced.
Dhingra NK, Verma S, Butler J, Anker SD, Ferreira JP, Filippatos G, Januzzi JL, Lam CSP, Sattar N, Zaremba-Pechmann L, Böhm M, Nordaby M, Brueckmann M, Pocock SJ, Zannad F, Packer M; EMPEROR-Reduced Trial Committees and Investigators. Dhingra NK, et al. Among authors: zaremba pechmann l. JACC Heart Fail. 2024 Jan;12(1):35-46. doi: 10.1016/j.jchf.2023.06.036. Epub 2023 Sep 13. JACC Heart Fail. 2024. PMID: 37715769 Free article. Clinical Trial.
Safety and Efficacy of Empagliflozin and Diuretic Use in Patients with Heart Failure and Preserved Ejection Fraction: A Post Hoc Analysis of the EMPEROR-Preserved Trial.
Butler J, Usman MS, Filippatos G, Ferreira JP, Böhm M, Brueckmann M, Januzzi JL, Kaul S, Piña IL, Ponikowski P, Senni M, Sumin M, Verma S, Zaremba-Pechmann L, Pocock SJ, Packer M, Anker S. Butler J, et al. Among authors: zaremba pechmann l. JAMA Cardiol. 2023 Jul 1;8(7):640-649. doi: 10.1001/jamacardio.2023.1090. JAMA Cardiol. 2023. PMID: 37223933 Free PMC article.
The RA-BE-REAL Multinational, Prospective, Observational Study in Patients with Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic, or Biologic Disease-Modifying Therapies: a 6-Month Interim Analysis.
Alten R, Burmester GR, Matucci-Cerinic M, Salmon JH, Lopez-Romero P, Fakhouri W, de la Torre I, Zaremba-Pechmann L, Holzkämper T, Fautrel B. Alten R, et al. Among authors: zaremba pechmann l. Rheumatol Ther. 2023 Feb;10(1):73-93. doi: 10.1007/s40744-022-00500-6. Epub 2022 Oct 13. Rheumatol Ther. 2023. PMID: 36227530 Free PMC article.
Treatment pathway analysis of newly diagnosed dementia patients in four electronic health record databases in Europe.
James G, Collin E, Lawrance M, Mueller A, Podhorna J, Zaremba-Pechmann L, Rijnbeek P, van der Lei J, Avillach P, Pedersen L, Ansell D, Pasqua A, Mosseveld M, Grosdidier S, Gungabissoon U, Egger P, Stewart R, Celis-Morales C, Alexander M, Novak G, Gordon MF. James G, et al. Among authors: zaremba pechmann l. Soc Psychiatry Psychiatr Epidemiol. 2021 Mar;56(3):409-416. doi: 10.1007/s00127-020-01872-2. Epub 2020 Jun 3. Soc Psychiatry Psychiatr Epidemiol. 2021. PMID: 32494994
Cost-Effectiveness of a JAK1/JAK2 Inhibitor vs a Biologic Disease-Modifying Antirheumatic Drug (bDMARD) in a Treat-to-Target Strategy for Rheumatoid Arthritis.
Van De Laar CJ, Oude Voshaar MAH, Fakhouri WKH, Zaremba-Pechmann L, De Leonardis F, De La Torre I, Van De Laar MAFJ. Van De Laar CJ, et al. Among authors: zaremba pechmann l. Clinicoecon Outcomes Res. 2020 Apr 15;12:213-222. doi: 10.2147/CEOR.S231558. eCollection 2020. Clinicoecon Outcomes Res. 2020. PMID: 32346301 Free PMC article.
Tiotropium Respimat Efficacy and Safety in Asthma: Relationship to Age.
Doherty DE, Bleecker ER, Moroni-Zentgraf P, Zaremba-Pechmann L, Kerstjens HAM. Doherty DE, et al. Among authors: zaremba pechmann l. J Allergy Clin Immunol Pract. 2020 Sep;8(8):2653-2660.e4. doi: 10.1016/j.jaip.2020.04.013. Epub 2020 Apr 19. J Allergy Clin Immunol Pract. 2020. PMID: 32320797 Free article.
Radiographic progression can still occur in individual patients with low or moderate disease activity in the current treat-to-target paradigm: real-world data from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry.
Ten Klooster PM, Versteeg LGA, Oude Voshaar MAH, de la Torre I, De Leonardis F, Fakhouri W, Zaremba-Pechmann L, van de Laar M. Ten Klooster PM, et al. Among authors: zaremba pechmann l. Arthritis Res Ther. 2019 Nov 12;21(1):237. doi: 10.1186/s13075-019-2030-8. Arthritis Res Ther. 2019. PMID: 31718678 Free PMC article. Clinical Trial.
19 results